News and Comments

ImmunoGen: What About Now?

  Friday, April 28, 2017

ImmunoGen is one of two firms Prohost selected for investment on February 2011 based on the promises of its novel antibody-drug conjugate (ADC). An ADC drug is an antibody that carries highly potent cancer-killing agent attached to the antibody by a linker. The linker is designed to release an exceptionally toxic agent only as the ADC reaches the cancer cells in order not to harm or kill healthy cells. Our enthusiasm for ADC products emanates from their potency compared to other antibodies and to their safety and potency compared to chemotherapy drugs. The dosage of the toxic agent in the monoclonal antibody conjugate is several times that of chemotherapy, hence the superior potency and tolerability expected from the ADC products.        More...

Immunogen: Defeating Advanced Ovarian Cancer And Other Malignancies

  Tuesday, June 02, 2015

- Immunogen’s recurrent ovarian cancer drug Mirvetuximab soravtansine (IMGN853) has demonstrated promising results. More...

Two Small Great Biotechs Underestimated by the Market

  Tuesday, June 25, 2013

Seattle Genetics’ (SGEN) and ImmunoGen’s (IMGN) conjugated monoclonal antibody therapeutics for cancer are increasingly validating their superior safety and efficacy over other cancer products that are used without the antibody drug conjugates (ADC).  More...

ImmunoGen Offers New Hopes For Treatment Of Subtypes Of Squamous Cell Carcinomas And Other Difficult-To-Treat Cancers

  Friday, April 12, 2013



  Monday, August 27, 2012

Targeted Antibody Payload (TAP) technology did not lie and we knew it and had never been skeptical about the fact that it is a superior technology for cancer treatment. Indeed, ImmunoGen’s (IMGN) lead TAP drug, trastuzumab emtansine for HER2 breast cancer continued to show its superiority over other cancer drugs and other delivery technologies that try to enhance oncology drugs’ efficacy, safety, or both. ImmunoGen’s TAP technology has demonstrated time and time again it improves both safety and efficacy and makes cancer drugs work after the same drugs fail to work when used alone, i.e., not within ImmunoGen’s targeted monoclonal antibody designed armed vehicle.  More...

Seattle Genetics: A powerful Approach For resistant Cancers Hits The Market

  Tuesday, August 23, 2011

We heard them all. We heard all they said, we mean the pessimist and the optimist following the approval of Seattle Genetics’ drug Adcentris™ (brentuximab vedotin) for Hodgkin lymphoma and for systemic anaplastic large cell lymphoma (ALCL). More...

Seattle Genetics: Adcentris Approved For Two Cancers

  Monday, August 22, 2011

Congratulations. A great technology, the antibody-drug conjugate (ADC) technology, which is perfected by the two biotech firms, Seattle Genetics (SGEN) and ImmunoGen (IMGN) has yielded the first approved drug. Yes, the FDA has granted accelerated approval of Adcentris™ (brentuximab vedotin) developed by Seattle Genetics (SGEN) for two indications:  More...

IMMUNOGEN: The TAP Technology

  Wednesday, June 15, 2011

Something to think about the fact that using ImmunoGen’s (IMGN) TAP technology makes targeted cancer drugs beat their own efficacy. This reality seems to be increasingly considered by cancer drug developers. Using ImmunoGen’s technology enables approved, or investigational targeted cancer drugs developed by pharmaceutical companies to gain extra-efficacy as first line treatments, in addition to overcoming cancer resistance in case of recurrences. The oncology drug developers would love to see their same products bring better safety and efficacy, cover more patients and succeed if recurrences occur. More...

ImmunoGen: No Exaggeration.

  Thursday, April 07, 2011

NO. It was not exaggerated, nor sophisticated what we wrote time and time again about the unparalleled safety and efficacy of the ImmunoGen’s Targeted Antibody Payload (TAP). It is no exaggeration announcing our conviction that cancer products based on Immunogen’s TAP   technology will generate billions of dollars in revenues. What we talked about has, indeed, become today’s great news.  More...

ImmunoGen: Steadfast Determination to Conquer Cancer

  Wednesday, April 06, 2011

The Program Committee of the 102nd Annual Meeting of the American Association for Cancer Research (AACR) taking place in Orlando, FL designated ImmunoGen’s (IMGN) cancer drug IMGN853 poster presentation “Highly Rated.” More...

Recent Postings



Bristol-Myers Squibb (BMY) CEMPRA (CEMP) Gilead (GILD) Biogen Idec (BIIB) Theravance Bio Pharma (TBPH) OncoCyte (OCX) JOUNCE THERAPEUTICS (JNCE) Seattle Genetics (SGEN) Dynavax (DVAX) Auspex (ASPX) INNOVIVA (INVA) Ionis (IONS) Global Cell Therapeutics (GBT) Alnylam (ALNY) RenenxBio (RGNX) BIOMARIN (BMRN) Amgen (AMGN) Galena (GALE) Trastuzumab-DM1 ADVENTRIX (ANX) Merck (MRK) Adaptimmune (ADAP) CompuGen (CGEN) REGULUS (RGLS) Regeneron (REGN) Roche (RHHBY) IDERA (IDRA) KITE (KITE) Herceptin HALOZYME (HALO) ImmunoGen (IMGN) Intercept (ICPT) Multiple Myeloma Roche (ROCHE) Sanofi-Aventis (SAN) Anacor (ANAC) NOVOCURE (NVCR) CRISPR Therapeutics (CRSP) Vertex (VRTX) Revlimid (lenolidamide) Agenus (AGEN) ACADIA (ACAD) TOKAI (TKAOI) Biocryst (BCRX) Sanofi (SNA) Akebia Therapeutics (AKAB) Benlysta (belimumab) GlaxoSmithKline (GSK) Inovio (INO) Alder Biopharmaceuticals (ALDR) SYNTA (SNTA) LEXICON (LXRX) Pluristem (PSTI) VANDA (VNDA) Elan (ELN) Mirati Therapeutics (MRTX) Human Genome Sciences (HGSI) Human Longevity (HLI) OSI (OSIP) Micromet (MITI) Velcade (bortezomib) NEUROCRINE (NBIX) Ziofpharm (ZIOP) ARCA (ABIO) Bellicum (BLCM) GUARDIAN HEALTH SERES THERAPEUTICS (MCRB) Tysabri ARGOS (ARGS) NANTKWEST (NK) GlycoMimetics (GLYN) Xoma (XOMA) Array Pharmaceuticals (ARRY) Advaxis (ADXS) Idenix (IDIX) JUNO (JUNO) AERIE PHARMACEUTICALS Sarepta (SRPT) Illumina (ILMN) Prolor Biotech (PBTH) Vitae Pharmaceuticals (VTAE) Valeant Pharmaceuticals International (VRX) Zerenex Dendreon (DNDN) Ocular Therapeutix (OCUL) KERYX (KERX) Genentech Abbott Laboratories (ABT) PORTOLA (PTLA) Theravance (THRX) Incyte (INCY) Onyx (ONXX) Aimmune Therapeutics (AIMT) PTC Therapeutics (PTCT) Cytokinetics (CYTK) AGOS (ARGS) Ariad (ARIA) Editas (EDIT) ZALTRAP™ Telaprevir AstraZeneca (AZN) Spike Therapeutics (ONCE) C4 Therapeutics Jazz Pharmaceuticals (JAZZ) Endometrial Cancer galapagos (GLPG) NEKTAR (NKTR)) Agenus (AGEN MODERNA Intermune (ITMN) Anadys (ANDS) Intrexon (XON) Prosensa (RNA) Epizyme (EPZM) ABBVIE (ABBV) Sanofi (SNY) Rapamune Sangamo (SGMO) SUNESIS PHARMACEUTICALS (SNSS) Ridaforolimus Sequenom (SQNM) ISIS (ISIS) Exelixis (EXEL)